Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024
Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC